← Leaderboards
Jeffrey L. Cummings
University Of California Los Angeles
$25,787,245
Attributed
$65,155,737
Total exposure
49
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $16.8M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$90,103,622 · 51
By mechanism
R01$39,370,197 · 1
P50$18,687,413 · 3
U01$16,987,966 · 1
P20$8,870,775 · 2
R35$2,913,255 · 1
M01$1,851,652 · 24
Top collaborators
- Eric M Reiman8 shared
- Martha Shenton8 shared
- Robert A Stern8 shared
- Paul S. Aisen6 shared
- Reisa A. Sperling6 shared
- Jamie Schwartz3 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Jason D Hinman$7,942,633
- Gerard A. Gioia$4,056,451
- Samuel French$1,098,049
- Royce H Johnson$278,534
- Natalie Melinda Shih$97,259
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseResearch PersonnelClinical ResearchGrantAlzheimer'S DiseaseResourcesDementiaUnited States National Institutes Of HealthFundingDatabasesProgramsInstitutionBiological MarkersFollow-UpDiagnosisAwardPublishingBrainClinical TrialsImageHuman SubjectMagnetic Resonance ImagingLife
Grant awards (114)
Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative$559,885
R35 · FY2025 · AG · contact PI
Alzheimer's Disease and Related Dementias Innovation Incubator (InnovaTor)$254,533
R25 · FY2025 · AG · contact PI
Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative$578,435
R35 · FY2024 · AG · contact PI
Alzheimer's Disease and Related Dementias Innovation Incubator (InnovaTor)$253,453
R25 · FY2024 · AG · contact PI
Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative$585,665
R35 · FY2023 · AG · contact PI
Alzheimer's Disease and Related Dementias Innovation Incubator (InnovaTor)$253,453
R25 · FY2023 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,856,514
R01 · FY2022 · AG
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,353,863
U01 · FY2022 · NS
Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative$591,645
R35 · FY2022 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,769,679
R01 · FY2021 · AG
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,259,927
U01 · FY2021 · NS
Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative$597,625
R35 · FY2021 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,845,298
R01 · FY2020 · AG
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,929,565
R01 · FY2020 · AG
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,069,619
U01 · FY2020 · NS
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,226,344
U01 · FY2019 · NS
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$589,149
U01 · FY2019 · NS
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,967,947
R01 · FY2018 · AG
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,448,976
U01 · FY2018 · NS
COBRE GRANT$1,936,240
P20 · FY2018 · GM · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$5,001,194
R01 · FY2017 · AG
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,466,073
U01 · FY2017 · NS
COBRE GRANT$2,230,641
P20 · FY2017 · GM · contact PI
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors$2,574,015
U01 · FY2016 · NS
COBRE GRANT$2,171,415
P20 · FY2016 · GM · contact PI
COBRE GRANT$2,167,171
P20 · FY2015 · GM · contact PI
CNTN Administrative Core$365,308
P20 · FY2015 · GM · contact PI
ADMINISTRATIVE CORE$385,251
P50 · FY2014 · AG · contact PI
ADMINISTRATIVE CORE$363,113
P50 · FY2013 · AG · contact PI
ADMINISTRATIVE CORE$446,229
P50 · FY2012 · AG · contact PI
ADMINISTRATIVE CORE$430,382
P50 · FY2011 · AG · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$20,081
P41 · FY2011 · RR · contact PI
ADMINISTRATIVE CORE$399,393
P50 · FY2010 · AG · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$3,039
P41 · FY2010 · RR · contact PI
UCLA Alzheimer's Disease Research Center$1,032,564
P50 · FY2009 · AG · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$6,798
P41 · FY2009 · RR · contact PI
UCLA Alzheimer's Disease Research Center$1,847,659
P50 · FY2008 · AG · contact PI
UCLA ALZHEIMER'S DISEASE CENTER DATABASE$29,588
M01 · FY2008 · RR · contact PI
DEMENTIA AND DISABILITY IN THAI ELDERLY$5,153
P41 · FY2008 · RR · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$5,153
P41 · FY2008 · RR · contact PI
GENETIC RISK FACTORS AS DETERMINANTS OF THE OUTCOME OF CLINICAL TRIALS IN ALZ$3,208
M01 · FY2008 · RR · contact PI
MULTICENTER ANALYSIS OF HIPPOCAMPAL MORPHOLOGY IN MCI$2,576
P41 · FY2008 · RR · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VALPROATE TO ATTENUAT$1,069
M01 · FY2008 · RR · contact PI
UCLA Alzheimer's Disease Research Center$1,895,130
P50 · FY2007 · AG · contact PI
UCLA ALZHEIMER'S DISEASE CENTER DATABASE$40,870
M01 · FY2007 · RR · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$20,076
P41 · FY2007 · RR · contact PI
MULTICENTER ANALYSIS OF HIPPOCAMPAL MORPHOLOGY IN MCI$20,076
P41 · FY2007 · RR · contact PI
DEMENTIA AND DISABILITY IN THAI ELDERLY$20,076
P41 · FY2007 · RR · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VALPROATE TO ATTENUAT$4,121
M01 · FY2007 · RR · contact PI
GENETIC RISK FACTORS AS DETERMINANTS OF THE OUTCOME OF CLINICAL TRIALS IN ALZ$3,434
M01 · FY2007 · RR · contact PI
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$687
M01 · FY2007 · RR · contact PI
UCLA Alzheimer's Disease Research Center$1,850,120
P50 · FY2006 · AG · contact PI
UCLA Alzheimer's Disease Research Center$54,040
P50 · FY2006 · AG · contact PI
UCLA ALZHEIMER'S DISEASE CENTER DATABASE$48,446
M01 · FY2006 · RR · contact PI
GENETIC RISK FACTORS AS DETERMINANTS OF THE OUTCOME OF CLINICAL TRIALS IN ALZ$10,410
M01 · FY2006 · RR · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VALPROATE TO ATTENUAT$6,406
M01 · FY2006 · RR · contact PI
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$5,078
P41 · FY2006 · RR · contact PI
MULTICENTER ANALYSIS OF HIPPOCAMPAL MORPHOLOGY IN MCI$5,078
P41 · FY2006 · RR · contact PI
DEMENTIA AND DISABILITY IN THAI ELDERLY$5,078
P41 · FY2006 · RR · contact PI
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$801
M01 · FY2006 · RR · contact PI
UCLA Alzheimer's Disease Research Center$1,807,202
P50 · FY2005 · AG
UCLA Alzheimer's Disease Research Center$38,639
P50 · FY2005 · AG
Dementia and Disability in Thai Elderly$32,693
R03 · FY2005 · TW
UCLA ALZHEIMER'S DISEASE CENTER DATABASE$25,698
M01 · FY2005 · RR
DEMENTIA AND DISABILITY IN THAI ELDERLY$4,910
P41 · FY2005 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$4,910
P41 · FY2005 · RR
MULTICENTER ANALYSIS OF HIPPOCAMPAL MORPHOLOGY IN MCI$4,910
P41 · FY2005 · RR
GENETIC RISK FACTORS AS DETERMINANTS OF THE OUTCOME OF CLINICAL TRIALS IN ALZ$2,310
M01 · FY2005 · RR
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$1,155
M01 · FY2005 · RR
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VALPROATE TO ATTENUAT$578
M01 · FY2005 · RR
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VITAMIN E AND ARICEPT$288
M01 · FY2005 · RR
UCLA Alzheimer's Disease Research Center$1,770,094
P50 · FY2004 · AG
ADMINISTRATIVE CORE$220,627
P50 · FY2004 · AG
UCLA Alzheimer's Disease Research Center$146,438
P50 · FY2004 · AG
Dementia and Disability in Thai Elderly$32,693
R03 · FY2004 · TW
NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMER'S DISEASE$13,763
P41 · FY2004 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$13,763
P41 · FY2004 · RR
MULTICENTER ANALYSIS OF HIPPOCAMPAL MORPHOLOGY IN MCI$13,763
P41 · FY2004 · RR
-K...$5,730
M01 · FY2004 · RR
Trial of Vitamin E and Aricept$4,366
M01 · FY2004 · RR
UCLA Alzheimer's Disease Research Center$2,000
P50 · FY2004 · AG
Assessment Measures for Alzheimer's Disease Primary Prevention Trials$1,910
M01 · FY2004 · RR
Treatment of Agitation/Psychosis in Dementia/Parkinsonis$273
M01 · FY2004 · RR
Effects of Testosterone/Placebo in Males w/Alzheimer's$273
M01 · FY2004 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$1,440,798
P50 · FY2003 · AG
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$145,570
P50 · FY2003 · AG
DEMENTIA AND BEHAVIORAL NEUROLOGY: RESEARCH FELLOWSHIP$53,835
T32 · FY2003 · AG
Dementia and Disability in Thai Elderly$39,193
R03 · FY2003 · TW
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$1,406,022
P50 · FY2002 · AG
DEMENTIA AND BEHAVIORAL NEUROLOGY: RESEARCH FELLOWSHIP$63,106
T32 · FY2002 · AG
IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE$0
P41 · FY2002 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$1,395,695
P50 · FY2001 · AG
MULTICENTER, PLACEBO CONTROLLED TRIAL OF MELATONIN FOR SLEEP DISTURBANCE$207,266
M01 · FY2001 · RR
SERTRALINE IN TREATMENT OF BEHAVIORS IN ALZHEIMERS PATIENTS$207,266
M01 · FY2001 · RR
SERTRALINE IN TREATMENT OF BEHAVIORS IN ALZHEIMERS PATIENTS$207,266
M01 · FY2001 · RR
EFFICACY OF THE XANOMELINE TRANSDERMAL THERAPEUTIC SYSTEM IN ALZHEIMER'S DISEASE$207,266
M01 · FY2001 · RR
EFFICACY OF THE XANOMELINE TRANSDERMAL THERAPEUTIC SYSTEM IN ALZHEIMER'S DISEASE$207,266
M01 · FY2001 · RR
METRIFONATE: EFFECTS ON BRAIN FUNCTION, BRAIN METABOLISM, &BEHAVIOR$207,266
M01 · FY2001 · RR
MULTICENTER, PLACEBO CONTROLLED TRIAL OF MELATONIN FOR SLEEP DISTURBANCE$207,266
M01 · FY2001 · RR
DEMENTIA AND BEHAVIORAL NEUROLOGY: RESEARCH FELLOWSHIP$103,821
T32 · FY2001 · AG
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$50,000
P50 · FY2001 · AG
IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE$48,533
P41 · FY2001 · RR
IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE$0
P41 · FY2001 · RR
IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE$0
P41 · FY2001 · RR
TRIAL OF VIT E/ARICEPT--COGNITION DISORDER THERAPY IN AD$0
M01 · FY2001 · RR
PHASE II TRIAL OF DONEPEZIL IN PTS WITH CVD DEMENTIA$0
M01 · FY2001 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$1,338,788
P50 · FY2000 · AG
METRIFONATE: EFFECTS ON BRAIN FUNCTION, BRAIN METABOLISM, &BEHAVIOR$207,266
M01 · FY2000 · RR
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$133,775
P50 · FY2000 · AG
DEMENTIA AND BEHAVIORAL NEUROLOGY: RESEARCH FELLOWSHIP$97,397
T32 · FY2000 · AG
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$50,000
P50 · FY2000 · AG
UCLA ALZHEIMERS DISEASE RESEARCH CENTER$37,884
P50 · FY2000 · AG
IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE$15,373
P41 · FY2000 · RR
METRIFONATE: EFFECTS ON BRAIN FUNCTION, BRAIN METABOLISM, &BEHAVIOR$1,903
M01 · FY2000 · RR